Last reviewed · How we verify

NCT04916262

Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer

Status unknown Last updated 16 June 2021
What this trial tests

trial in Differentiated Thyroid Carcinoma in 160 participants. Status unknown.

Timeline
20 June 2021
Primary endpoint
1 December 2021
1 January 2022

Quick facts

Lead sponsorQianfoshan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment160
Start date20 June 2021
Primary completion1 December 2021
Estimated completion1 January 2022

Conditions studied

Sponsor

Qianfoshan Hospital

Who can join

Adults 18 to 75, any sex, with Differentiated Thyroid Carcinoma or TCM Syndrome Type. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to make a dialectical classification of patients who will receive 131I treatment after operation of thyroid cancer from the point of view of dialectics of syndrome elements of traditional Chinese medicine. By observing the changes of TSH among patients with different syndrome types, investigators can better understand the reasons for the differences in TSH changes among patients. Thus, it provides a basis for putting forward the scheme of stopping taking levothyroxine before iodine treatment, improving the quality of life of patients after radical thyroidectomy, and providing reference for individualized guidance of the timing of radioactive iodine therapy for patients after DTC.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Qianfoshan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04916262.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing